Institute for Cancer Research
Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.
The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.
Scientific production - Institute for Cancer Research
Annual report 2015 (pdf format)
Welcome to the next Oslo University Hospital research seminar entitled "Immunotherapy for Cancer".
Time: Tuesday, April 25th, 2017, at 10:00-15:45.
Place: Store Auditorium, Rikshospitalet, Sognsvannsveien 20, Oslo.
Note that there is a limited number of seats. Please sign up at:
Replication forks must be stabilized in order to avoid DNA breakage and recombination. In a study recently published in Nucleic Acids Research entitled “SeqA structures behind Escherichia coli replication forks affect replication elongation and restart mechanisms“ researchers in the Skarstad group show that double strand breaks are generated in the absence of fork-trailing SeqA structures and that cells then have lost the ability to perform direct (RecA-independent) restart of replication forks. The two first authors are Ida Benedikte Pedersen and Emily Helgesen (photo).
The American Association for Cancer Research (AACR) - Women in Cancer Research (WICR) Charlotte Friend Memorial Lectureship was established in 1998 in honour of renowned virologist and discoverer of the Friend virus, Dr. Charlotte Friend. The WICR Friend Lectureship is presented to an outstanding scientist who has made meritorious contributions to the field of cancer research and who has, through leadership or by example, furthered the advancement of women in science.
Anne-Lise Børresen-Dale, professor emerita at the Department of Cancer Genetics at the Institute for Cancer Research, OUH, has been chosen as the 20th Annual Award Recipient. Her award lecture will be held on April 3rd in the Washington Convention Center.
K.G.Jebsen Colorectal Cancer Research Centre scientists participated with data from patients admitted to OUH in a multicenter study of >7000 stage II and III CRC recently reported in Annals of Oncology (Dienstmann et al).
Incorporation of MSI, BRAFV600E and KRAS mutation status to overall survival models with TNM staging improves the ability to precisely prognosticate in stage II and III CC patients, but only modestly increases prediction accuracy in multivariable models that include clinicopathological features, particularly in chemotherapy-treated patients.
“Centre for Cancer Cell Reprogramming”, affiliated with the Institute of Clinical Medicine at University of Oslo, has been funded by the Research Council of Norway as a new Centre of Excellence.
Jørgen Wesche appointed group leader for the Mesenchymal Cancer Biology Group at the Department of Tumor Biology
Jørgen Wesche earned his PhD in Sjur Olsnes's group in 2001, studying intracellular transport and membrane translocation. During his postdoctoral training, spending some time at Institute Curie in Paris, he has changed his focus towards problems with more translational relevance, specializing in live cell imaging, fibroblast growth factor receptor (FGFR) signaling and importance of FGFR in cell migration/invasion. Aberrations in FGFR signaling are found in several types of sarcoma and that´s the main reason way Jørgen started to get interested in sarcoma biology and treatment. He has several exciting ideas on how to further develop his research into more translational/clinical relevance.
Apr 19, 2017
Inst. for Cancer Research
Mapping the Synthetic Dosage Lethality Network of CDK1/CDC28
G3 (Bethesda) (in press)
Pathway-based classification of breast cancer subtypes
Front Biosci (Landmark Ed), 22, 1697-1712
Journal Impact Factor > 5, first or last author from the Institute for Cancer Research
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
Breast Cancer Res, 19 (1), 44
Lipids in exosomes: Current knowledge and the way forward
Prog Lipid Res, 66, 30-41 (in press)